Fig. 7From: Recombinant lipoprotein-based vaccine candidates against C. difficile infectionsMouse protection elicited by rlipoA-RBD against lethal TcdA challenge. Panel a, BALB/c mice (10 mice per group) were challenged with a lethal dose of TcdA after three immunizations of either rlipoA-RBD or A-rRBD (0.3 and 3 ug). PBS served as the negative control. The final survival rates were reported. Panel b, BALB/c mice (10 mice per group) were challenged with a lethal dose of TcdA after three immunizations of either rlipoA-RBD (0.3 and 3 μg) or 30 μg of B-rRBDBack to article page